Labella (Levonorgestrel)

Levonorgestrel binds to progesterone receptors, suppressing the luteinizing hormone surge and preventing ovulation. It also thickens cervical mucus, reduces tubal motility, and alters the endometrium, making it difficult for fertilization and implantation to occur.

The specific dose and regimen of Labella are determined by the prescribing healthcare professional based on the indication and patient characteristics. Patients should follow the prescriber’s instructions and not alter the dose on their own.

Labella is intended to prevent pregnancy and should not be used by women who are already pregnant. Limited data are available for breastfeeding; however, levonorgestrel is excreted in small amounts in breast milk, and the benefits and risks should be discussed with a healthcare provider.

To order Labella, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Labella’s active ingredient, levonorgestrel, is a widely used progestin that offers effective pregnancy prevention when taken within 72‑120 hours. Compared with copper IUDs, it is less invasive but has a shorter window of efficacy; compared with ulipristal acetate, it may be slightly less effective beyond 72 hours but is more widely available.

Labella tablets should be stored at room temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the product out of reach of children and do not use if the packaging is damaged.

Labella is taken orally as a tablet. For emergency use, the tablet is swallowed with water as soon as possible after unprotected intercourse, following the prescriber’s timing guidance. For regular contraception, the dosing schedule is defined by the healthcare provider.

Serious risks, though rare, include severe allergic reactions (anaphylaxis), chest pain indicating possible cardiovascular events, severe abdominal pain that may signal an ectopic pregnancy, and significant liver dysfunction. Patients should seek immediate medical attention if any of these symptoms occur.

Labella should not be used by women who are already pregnant, have known hypersensitivity to levonorgestrel, have active breast cancer, or have severe liver disease. Individuals taking certain enzyme‑inducing medications should consult their provider, as efficacy may be reduced.